In a wide-ranging conversation, CEO John Evans discussed Beam’s pipeline and other preclinical programs. He described the improved safety profile of genome editing therapies, and talked about Beam’s multi-faceted approach when it comes to finding the right delivery vehicle. Evans also talked about Beam’s relationship with Prime Medicine, another David Liu-founded entity, which announced its launch shortly after this interview was recorded with a series A/B round of $315 million . . .
